Close Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$430K Hold
2,545
0.01% 109
2025
Q4
$430K Buy
2,545
+2,200
+638% +$357K 0.01% 111
2025
Q3
$50K Buy
345
+70
+25% +$9.55K ﹤0.01% 171
2025
Q2
$35K Hold
275
﹤0.01% 179
2025
Q1
$35K Buy
275
+45
+20% +$6.1K ﹤0.01% 168
2024
Q4
$30K Hold
230
﹤0.01% 173
2024
Q3
$33K Hold
230
﹤0.01% 180
2024
Q2
$32K Hold
230
﹤0.01% 179
2024
Q1
$32K Hold
230
﹤0.01% 176
2023
Q4
$31K Sell
230
-78
-25% -$9.52K ﹤0.01% 168
2023
Q3
$38K Hold
308
﹤0.01% 152
2023
Q2
$39K Hold
308
﹤0.01% 168
2023
Q1
$40K Buy
308
+78
+34% +$10.2K ﹤0.01% 151
2022
Q4
$30K Hold
230
﹤0.01% 143
2022
Q3
$27K Hold
230
﹤0.01% 134
2022
Q2
$27K Buy
+230
New +$27.3K ﹤0.01% 135
2018
Q1
Sell
-75
Closed -$8K 226
2017
Q4
$8K Hold
75
﹤0.01% 193
2017
Q3
$8K Buy
+75
New +$8.02K ﹤0.01% 183

Other funds holding IBB

Close Asset Management's IBB Position: Q1 2026 in Review

Close Asset Management held its iShares Biotechnology ETF (IBB) position steady in Q1 2026 at 2,545 shares worth $430K. The position accounts for 0.01% of the portfolio, ranked #109.

Close Asset Management first reported a position in IBB in Q3 2017 and has held it in 18 quarters since. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Close Asset Management held 2,545 shares of iShares Biotechnology ETF worth $430K as of Q1 2026.
  • Close Asset Management left its iShares Biotechnology ETF share count unchanged in Q1 2026.
  • iShares Biotechnology ETF made up 0.01% of Close Asset Management's portfolio in Q1 2026, its #109 holding.
  • Close Asset Management first reported a position in iShares Biotechnology ETF in Q3 2017 and has held it in 18 quarters since.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Close Asset Management's 13F filing for Q1 2026, filed 12 May 2026.